BCU Strengthens Jack Henry Relationship to Support Growth Goals
Get Alerts JKHY Hot Sheet
Join SI Premium – FREE
BCU first selected
Today, BCU has grown to
"We've been on a cloud journey for years, shifting our focus from infrastructure management to innovation that directly benefits our members," said
BCU values the ability to leverage
"The team at BCU is a prime example of how embracing the disruption occurring in the financial technology ecosystem can support long-term growth and innovation," said
About Jack Henry & Associates, Inc.®
Jack Henry™ (Nasdaq: JKHY) is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. We are an S&P 500 company that prioritizes openness, collaboration, and user centricity – offering banks and credit unions a vibrant ecosystem of internally developed modern capabilities as well as the ability to integrate with leading fintechs. For more than 48 years, Jack Henry has provided technology solutions to enable clients to innovate faster, strategically differentiate, and successfully compete while serving the evolving needs of their accountholders. We empower approximately 7,500 clients with people-inspired innovation, personal service, and insight-driven solutions that help reduce the barriers to financial health. Additional information is available at www.jackhenry.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/bcu-strengthens-jack-henry-relationship-to-support-growth-goals-302422299.html
SOURCE Jack Henry & Associates, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- REDICO and One Orchard launch InfraMed Properties -- a medical outpatient investment platform poised for nationwide growth
- Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides
- Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share